Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Completed · Phase 2 · NCT04922554
Conditions: Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
At a glance
- Research payments reported, 2025
- $409,928
- U.S. investigators named
- 25
- Sites paid
- 22
- Planned or actual enrollment
- 66
About the trial
- Sponsor
- Paratek Pharmaceuticals Inc
- Tested
- Omadacycline Oral Tablet (drug), Placebo (drug)
- Dates
- Started 2021-10-15; completion 2024-07-17
- Results posted
- Yes
The purpose of this study is to evaluate the efficacy, safety and tolerability of oral omadacycline as compared to placebo in the treatment of adults with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc)
From ClinicalTrials.gov, last updated 2025-07-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Paratek Pharmaceuticals, Inc. reported $409,928 in research payments for this study in 2025 (68 payments).
Products named: Nuzyra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Stephen Ruoss, M.D. Critical Care Medicine · Stanford, CA
- Anne E. O'donnell Pulmonology · Washington, DC
- Mohamed I. Ali Eltoum, M.D. Pulmonology · Saint Petersburg, FL
- Francis J. Averill, MD Pulmonology · Clearwater, FL
- Lisa M. Domaradzki, M.D. Pulmonology · Miami, FL
- Tabarak A. Qureshi, MD Pulmonology · Altamonte Springs, FL
- Chakrapol Sriaroon, M.D. Pulmonology · Tampa, FL
- Laurie A. Welton, DO Infectious Disease · Sebastian, FL
- Steven Goudy, MD ENT (Otolaryngology) · Atlanta, GA
- Colin Swenson, M.D. Pulmonology · Atlanta, GA
- Juzar Ali, MD.,FRCP., FCCPC Pulmonology · New Orleans, LA
- Nicole C. Lapinel, M.D. Pulmonology · New Orleans, LA
- Christopher K. Lippincott, M.D. Internal Medicine · Baltimore, MD
- Kenneth N. Olivier, M.D. Pulmonology · Bethesda, MD
- Andrej Spec, MD Infectious Disease · Saint Louis, MO
- Reginald J. Fowler JR., MD Critical Care Medicine · Winston-salem, NC
- Elizabeth A. Talbot, MD Infectious Disease · Lebanon, NH
- Sherif G. El Bayadi, MD Pulmonology · Syracuse, NY
- Eric A. Meyerowitz, M.D. Infectious Disease · Bronx, NY
- Kevin L. Winthrop, MD Infectious Disease · Portland, OR
- Patrick A. Flume, MD Pulmonology · Charleston, SC
- Pamela J. Mcshane, M.D. Pulmonology · Tyler, TX
- Mehdi Mirsaeidi, M.D Pulmonology · Austin, TX
- Julie V. Philley, MD Pulmonology · Tyler, TX
- Elizabeth A. Misch, MD Infectious Disease · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Medical University of South Carolina $67,756
- Biomedical Research Alliance of New York LLC $49,650
- Dartmouth Hitchcock Clinic $43,762
- Johns Hopkins University $39,640
- Ohsu Hospital and Clinics, OR $27,756
- The University of South Florida Board of Trustees $23,618
- Louisiana State University Health Sciences Center in New Orleans $20,941
- University of Texas Health Science Center at Tyler, TX $17,946
- University of North Carolina at Chapel Hill $17,424
- Infectious Diseases Consultants of the Treasure Coast PA $17,062
- Georgetown University $16,880
- The Board of Trustees of the Leland Stanford Junior University $12,081
- St Francis Holdings LLC $10,860
- St Josephs Medical PC $9,951
- Emory University Hospital, GA $8,582
- University of Florida $7,930
- Central Florida Pulmonary Group PA $4,601
- University of Miami $4,026
- The Washington University $3,817
- Board of Regents of the University of Wisconsin System $2,893
- Southeastern Research Center LLC $2,001
- Pasadena Center for Medical Research LLC $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.